Nutrition 21, Inc., has released results of a new study reaffirming the safety of Chromax chromium picolinate to be published in an upcoming issue of Mutation Research Genetic Toxicology and Environmental Mutagenesis. The results found that Chromax did not cause genetic damage in hamster ovary cells. It was conducted at the request of the U.K. Food Standards Agency (FSA) to repeat a previously published study showing DNA damage. The prior study was not performed under International Conference on Harmonization (ICH) Guidelines and did not use commercially available chromium picolinate.

In other news, the company has released results from a new clinical study that add to the growing body of clinical data demonstrating that daily supplementation with Diachrome, a combination of chromium picolinate and biotin, can significantly reduce cardiovascular disease risk factors in people with type 2 diabetes. Findings from the randomized, double-blind, placebo-controlled trial were presented at the 2nd International Symposium on Triglycerides and HDL: Role in Cardiovascular Disease and the Metabolic Syndrome. The study analyzed individuals with type 2 diabetes who were moderately obese and taking oral anti-diabetic medications. When Diachrome was added to daily treatment regimens, the atherogenic index of plasma (AIP), a predictive marker for cardiovascular disease that examines triglyceride and HDL cholesterol levels (good cholesterol), was significantly lower compared with the placebo group. The AIP in the Diachrome group dropped from 1.15 to 1.06, while it increased from 1.27 to 1.55 in the placebo group. A significant difference in triglycerides and cholesterol levels was also observed between the groups.

For further information: 847-676-4337.